Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc and INSTI Switch in HIV-1
NCT01896921Phase 3Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Sep 2013
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of maraviroc, raltegravir and dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of Maryland, Baltimore. Started Sep 2013; status: completed.
02
Drugs
maravirocraltegravirdolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01896921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01896921.